Skip to main content
main-content

01.12.2018 | Letter | Ausgabe 1/2018 Open Access

Arthritis Research & Therapy 1/2018

Early achievement of deep remission predicts low incidence of renal flare in lupus nephritis class III or IV

Zeitschrift:
Arthritis Research & Therapy > Ausgabe 1/2018
Autoren:
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa, Kimito Kawahata
Abbreviations
CR
Complete renal response
EULAR/ERA-EDTA
The Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association
LN
Lupus nephritis
SDI
Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index
UPCR
Urine protein:Cr ratio

Recommendations for lupus nephritis (LN) management specify that the therapeutic target should be a complete renal response (CR) [ 1], defined as a urine protein:Cr ratio (UPCR) of 0.5 g/gCr (50 mg/mmol) and normal or near-normal renal function. Earlier studies suggested that patients who achieved CR experienced fewer renal flares than those who achieved partial remission, defined as a 50% reduction of proteinuria [ 2]. Among patients who achieved CR (less than 0.50 g/gCr of UPCR), however, the renal outcome of those who achieved a value below the normal UPCR limit of 0.15 g/gCr was unclear. We recently reported that an early renal response may predict a good renal or systemic outcome [ 3, 4]. In this study, we investigated whether it is beneficial to achieve deep remission early by evaluating flare rate, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI), cumulative glucocorticoid dose, and eGFR level.
We retrospectively assessed 69 patients with biopsy-proven LN class III or IV who achieved CR in our hospital. We divided them into two groups based on whether deep remission was achieved, defined as less than 0.15 g/gCr UPCR, and compared cumulative flare rates [ 1], defined as estimated glomerular filtration rate (eGFR) decreasing by ≥ 10%, active urine sediment, or increasing UPCR > 1.0 g/gCr after achieving CR. Furthermore, we analyzed the additional effect of early achievement of CR, defined as CR within 3 months after induction therapy. Clinical characteristics between the two groups were compared using the non-parametric Mann-Whitney U-test. Frequencies of clinicopathological characteristics were compared using the Chi-square test. Cumulative flare free rates were calculated using the Kaplan-Meier method, and differences between the two groups were tested with a log-rank test. To identify independent parameters that predict CR at 3 years, we performed multivariate analysis.
During the 3-year period, 55 of 69 CR patients achieved deep remission while 14 did not. Among clinical features at baseline, the proportion of females was significantly higher among patients with deep remission ( p = 0.01; Table  1).
Table 1
Baseline clinical and renal pathological features of LN patients with or without deep remission
Baseline characteristics
Deep remission
p
Achieved ( n = 55)
Not achieved ( n = 14)
Sex (percentage female)
48 (87.3)
9 (64.2)
0.01
Age (years)
39.1 ± 12.4
39.9 ± 10.7
0.3
BMI (kg/m 2)
22.4 ± 3.3
20.9 ± 2.3
0.5
Systolic blood pressure (mmHg)
127.8 ± 17.0
136.4 ± 21.5
0.2
Diastolic blood pressure
79.7 ± 13.6
83.6 ± 14.5
0.3
Disease duration (years)
5.1 ± 6.8
8.0 ± 6.4
0.4
SLEDAI
15.6 ± 4.8
13.0 ± 4.8
0.4
SDI
0.4 ± 0.6
0.6 ± 0.8
0.7
Proteinuria (g/gCr)
2.7 ± 2.1
3.7 ± 1.8
0.07
eGFR (mL/min)
76.6 ± 28.2
72.2 ± 32.8
0.9
Anti-dsDNA antibody (IU/mL)
177 ± 274
112 ± 116
0.6
Anti-cardiolipin antibody (IU/mL)
21.8 ± 30.7
14.7 ± 28.5
0.5
Lupus anticoagulant-positive (%)
3 (5.5)
1 (7.1)
0.6
CH50 (U/ml)
17.1 ± 9.3
24.4 ± 14.2
0.06
Prednisolone (mg/day)
45.5 ± 15.1
37.1 ± 10.1
0.08
Induction therapy
 IVCY (%)
29 (52.7)
5 (35.7)
0.4
 MMF (%)
8 (14.5)
2 (14.3)
0.9
 Tacrolimus (%)
8 (14.5)
2 (14.3)
0.9
 PSL monotherapy (%)
6 (10.9)
2 (14.3)
0.8
 Others (%)
4 (7.3)
3 (21.4)
0.1
Renal pathological findings
 ISN/RPS classification
  III or III + V (%)
26 (47.3)
5 (35.7)
0.4
  IV or IV + V (%)
29 (52.7)
9 (64.3)
0.4
Endocapillary hypercellularity (%)
39.2 ± 18.6
46.0 ± 30.2
0.5
Leukocyte infiltration (%)
2.0 ± 4.9
2.2 ± 4.1
0.4
Subendothelial hyaline deposits (%)
29.1 ± 30.2
30.1 ± 28.9
0.3
Fibrinoid necrosis/karyorrhexis (%)
7.0 ± 11.1
8.1 ± 18.1
0.3
Cellular crescents (%)
7.0 ± 11.1
8.1 ± 18.1
0.7
Interstitial inflammation (%)
2.1 ± 3.7
2.3 ± 7.4
0.5
Glomerular sclerosis (%)
2.5 ± 7.1
3.9 ± 8.2
0.4
Fibrous crescents (%)
2.1 ± 2.0
2.2 ± 3.1
0.7
Tubular atrophy (%)
2.8 ± 4.7
3.3 ± 5.9
0.5
Interstitial fibrosis (%)
4.7 ± 6.8
5.1 ± 5.9
0.6
Activity index
5.2 ± 3.0
5.1 ± 3.8
0.5
Chronicity index
1.4 ± 0.4
1.4 ± 1.3
0.7
dsDNA double-stranded DNA, IVCY intravenous cyclophosphamide, MMF mycophenolate mofetil, SDI Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, SLEDAI Systemic Lupus Erythematosus Disease Activity Index
We found a significantly higher flare-free rate among patients who achieved deep remission compared with those who did not ( p = 0.001; Fig.  1a). For patients with deep remission, those with early CR had a higher flare-free rate than those without ( p = 0.04) (Fig.  1b), but significant difference was found in those with non-deep remission (Fig.  1c). Multivariate analysis to predict sustained CR indicated that early achievement of deep remission was an independent factor (odds ratio 3.62, 95% confidence interval 1.1–18.9, p = 0.05). Regarding SDI, cumulative glucocorticoid dose, and eGFR level at year 3, patients with early deep remission had the most favorable result compared to the other groups (Fig.  2).
In this study, we found that achieving early and deep remission predicts a good renal outcome in patients with LN class III or IV. Since renal flare predicts a worse prognosis [ 5], determining the method of treatment to ensure long-term maintenance of CR is challenging. Our results suggest that deep remission might be a more beneficial therapeutic goal than that of the EULAR/ERA-EDTA recommendations regarding the prevention of renal flare. A future multi-center, prospective study is required to confirm our findings.

Availability of data and materials

The datasets used in the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

This study was approved by the Ethics Committee of St. Marianna University School of Medicine. The reference number is 3305.

Consent for publication

Since this study was conducted under a retrospective cohort design without any samples taken besides those for clinical use, written informed consent was not acquired, in accordance with the guideline of Ministry of Health, Labour and Welfare of Japan.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

Arthritis Research & Therapy 1/2018 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin 

Bildnachweise